Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 3 Lymphoma, Large B-Cell, Diffuse 2 Recurrence 1 Lymphoma 1 HIV Infections 1

Interventions

Cyclophosphamide 41 fludarabine 31 Dexamethasone 27 venetoclax 25 Cytarabine 22 Rituximab 16 pembrolizumab 15 fludarabine phosphate 14 Filgrastim 12 Etoposide 12 Lenalidomide 11 Vincristine 10 Gemcitabine 10 Azacitidine 10 pomalidomide 9 Interleukin-2 9 Granulocyte Colony-Stimulating Factor 9 Doxorubicin 9 Calcium Dobesilate 9 carfilzomib 8 Topotecan 8 Nivolumab 8 Methotrexate 8 Everolimus 8 Decitabine 8 Bortezomib 8 Melphalan 7 Cisplatin 7 Vorinostat 6 Injections 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recurrence × axicabtagene ciloleucel × Clear all

NCT04608487 2025-07-30

Axi-cel in CNS Lymphoma

Dana-Farber Cancer Institute

Phase 1 Active not recruiting

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡